CYP3A5 Gene-Guided Tacrolimus Treatment of Living-Donor Egyptian Kidney Transplanted Patients.
| Autor: | Mendrinou E; Department of Pharmacy, School of Health Sciences, University of Patras, Patras, Greece., Mashaly ME; The Urology-Nephrology Center, Department of Dialysis and Transplantation, Mansoura University, Mansoura, Egypt., Al Okily AM; Department of Nephrology, Zagazig University, Zagazig, Egypt., Mohamed ME; Department of Nephrology, Zagazig University, Zagazig, Egypt., Refaie AF; The Urology-Nephrology Center, Department of Dialysis and Transplantation, Mansoura University, Mansoura, Egypt., Elsawy EM; Urology and Nephrology Center, Department of Laboratories, Mansoura University, Mansoura, Egypt., Saleh HH; Urology and Nephrology Center, Department of Laboratories, Mansoura University, Mansoura, Egypt., Sheashaa H; The Urology-Nephrology Center, Department of Dialysis and Transplantation, Mansoura University, Mansoura, Egypt., Patrinos GP; Department of Pharmacy, School of Health Sciences, University of Patras, Patras, Greece.; Zayed Center of Health Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates.; Department of Pathology, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in pharmacology [Front Pharmacol] 2020 Aug 11; Vol. 11, pp. 1218. Date of Electronic Publication: 2020 Aug 11 (Print Publication: 2020). |
| DOI: | 10.3389/fphar.2020.01218 |
| Abstrakt: | Background: Tacrolimus is an approved first-line immunosuppressive agent for kidney transplantations. Part of interindividual and interethnic differences in the response of patients to tacrolimus is attributed to polymorphisms at CYP3A5 metabolic enzyme. CYP3A5 gene expression status is associated with tacrolimus dose requirement in renal transplant recipients. Materials and Methods: In this study, we determined the allelic frequency of CYP3A5*3 in 76 renal transplanted patients of Egyptian descent. Secondly, we evaluated the influence of the CYP3A5 gene variant on tacrolimus doses required for these patients as well on dose-adjusted tacrolimus trough-concentrations. Results: The CYP3A5*3 variant was the most frequent allele detected at 85.53%. Additionally, our results showed that, mean tacrolimus daily requirements for heterozygous patients ( CYP3A5*1/*3 ) were significantly higher compared to homozygous patients ( CYP3A5*3/*3 ) during the first year after kidney transplantation. Conclusion: This is the first study in Egypt contributing to the individualization of tacrolimus dosing in Egyptian patients, informed by the CYP3A5 genotype. (Copyright © 2020 Mendrinou, Mashaly, Al Okily, Mohamed, Refaie, Elsawy, Saleh, Sheashaa and Patrinos.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|